3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Lymphoid
1
Conditions
Neoplasms
3
Multiple Myeloma
3
Lymphoma, Non-Hodgkin
3
Lymphoma
3
Hodgkin Disease
3
Breast Neoplasms
3
Sezary Syndrome
2
Primary Myelofibrosis
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Pdgfra-Associated Chronic Eosinophilic Leukemia
2
Neoplasms, Plasma Cell
2
Myeloproliferative Disorders
2
Myelodysplastic-Myeloproliferative Diseases
2
Myelodysplastic Syndromes
2
Mycosis Fungoides
2
Lymphoma, T-Cell, Cutaneous
2
Lymphoma, Mantle-Cell
2
Lymphoma, Large-Cell, Immunoblastic
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma, Follicular
2
Lymphoma, B-Cell, Marginal Zone
2
Leukemia, Neutrophilic, Chronic
2
Leukemia, Myelomonocytic, Chronic
2
Leukemia, Myeloid, Chronic-Phase
2
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
2
Leukemia, Myeloid, Acute
2
Leukemia, Myeloid, Accelerated Phase
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Leukemia, Hairy Cell
2
Leukemia
2
Interventions
telavancin
1
ceftolozane, tazobactam drug combination
1
Moxifloxacin
1
Heparin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Bacteremia
×
Moxifloxacin
×
Clear all
NCT00398411
2015-06-29
MoxiProph
University of Cologne
Phase 3
Completed
66 enrolled
15 charts